Unlock instant, AI-driven research and patent intelligence for your innovation.

Substrate for biological fluid treatment

A liquid processing and biological technology, applied in the field of substrates for biological liquid processing, can solve problems that have not yet been established

Inactive Publication Date: 2009-07-08
ASAHI KASEI KK
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These are difficult to maintain practically sufficient binding activity in the state of being immobilized on the substrate surface
[0017] Although it is expected to directly and specifically capture cells from target substances in such biochemical fluids represented by blood, especially from whole blood, it has not yet been established as a practically usable technology.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substrate for biological fluid treatment
  • Substrate for biological fluid treatment
  • Substrate for biological fluid treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Example 1: Production of Leu3a scFv-SA body

[0097] (Production of the gene of the Leu3a single-chain antibody)

[0098] The nucleic acid sequence of the mouse anti-human CD4 monoclonal antibody Leu3a is disclosed in Genbank Accesion No. M97867.1 for the VH site and Genbank Accession No. M61046.1 for the VL site. In order to make these sequences into single-chain antibodies, a nucleic acid encoding a 15-amino acid sequence (SEQ ID NO: 1 in the Sequence Listing) as a Linker was designed to be linked, and the sequence of VL-linker-VH was completely synthesized. make. In this case, an Nco I site was added directly in front of the VL site so as to include an initiation codon (start codon), and a Not I site was added at the end of the VH site. These nucleic acids were subcloned into pUC57 vector.

[0099] The complete synthesis and subcloning of the above-mentioned nucleic acid sequences utilized the synthesis contract service provided by GenScript Corporation of the Uni...

Embodiment 2

[0110] Example 2: Expression, recovery under guanidine hydrochloride denaturing conditions

[0111] The expression vector constructed in Example 1 was transformed into Escherichia coli BL21 (DE3) strain (NOVAGEN Company) according to the instructions. It was cultured at 37° C. in a 2×YT medium (1.6% Bacto tryptone, 1% Bacto yeast lactate, 0.5% NaCl) containing 34 μg / ml kanamycin and 1% glycerol. The culture was stopped when the absorbance OD at 600 nm reached 0.7-0.8, and glycerol stock (stock) was prepared with a final concentration (final) of 15% glycerol, and stored at -80°C. This preserved 1 ml glycerol stock was mixed with 300 ml of 2×YT medium containing 34 μg / ml kanamycin and 1% glycerol, and cultured at 37°C. When the absorbance OD at 600 nm reached 0.7 to 0.8, IPTG (TAKARA Co.) was added at a final concentration of 1 mM, and cultured at 37° C. for another 4 hours. The Escherichia coli culture suspension was transferred to a 500 ml centrifuge tube, centrifuged at 4,0...

Embodiment 3

[0115] Example 3: Refolding purification under urea stage dilution dialysis

[0116] Use Slide-A-Lyzer (molecular weight cut-off 10kD: PIERCE company) to dilute about 30 ml of the refined liquid of Leu3a scFv-SA protein that is soluble under the denaturation of guanidine hydrochloride as in the first half of Example 2 and dilute with urea 1 L of dialyzed external fluid (50 mM Tris-HCl pH=8.0, 300 mM NaCl, 4 M urea) was dialyzed overnight at room temperature. Then, 1 L of the dialyzed fluid (50 mM Tris-HCl pH=8.0, 300 mM NaCl, 2 M urea, 400 mM L-arginine, 375 μM oxidized glutathione) was diluted with the urea phase of the second stage and dialyzed at room temperature for 24 hours. Then, in order to prevent the formation of a precipitate after the stereostructure refolding of the Leu3a scFv-SA protein, take out 5ml of the refined product of the Leu3a scFv-SA protein in the above-mentioned stage dilution dialysis, and dilute the dialyzed external fluid (50mM Tris-HCl pH=8.0, 300...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
degree of graftingaaaaaaaaaa
degree of graftingaaaaaaaaaa
Login to View More

Abstract

It is an object of the present invention to provide a practically applicable substrate for blood treatment for specifically capturing a target substance such as a cell directly from the whole blood, and an inexpensively and industrially applicable substrate for biological fluid treatment which is capable of separating a target substance directly from a biological fluid. The present invention provides a substrate for biological fluid treatment in which a recognition molecule having a selective binding property for a target substance is covalently immobilized on a surface of the substrate, wherein the recognition molecule is a linear molecule comprising a ligand moiety and an association domain, and at least four or more recognition molecules form an assembly structure.

Description

technical field [0001] The present invention relates to a substrate for biological fluid treatment for specifically adsorbing or removing a separation object from a biological fluid represented by blood or the like, and its use. Background technique [0002] The so-called blood purification therapy refers to the treatment for the purpose of maintaining the homeostasis in the living body by removing substances from the blood that are considered to be related to its onset, induction, and deterioration (acceleration) in order to treat a specific disease. It is called apheresis (Apheresis) treatment. Currently performed blood purification therapy can be classified into 4 categories according to the components to be removed and the removal mechanism. [0003] (1) Hemodialysis, hemofiltration, and hemodialysis therapy: suitable for acute renal failure, chronic renal failure, etc. It is a therapy to directly purify the components (low molecular weight components such as urea and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61M1/36B01J20/24
CPCC07K16/2803C07K16/2812G01N33/54353C07K2317/622A61M1/3679B01D15/00C07K17/06B01J20/32B01J20/3242G01N33/6857C07K16/065B01J20/3204B01J20/321B01J20/3212B01J20/3219B01J20/3274A61M1/15
Inventor 草加孝之野村昌行前田拓郎杉山雄也
Owner ASAHI KASEI KK